NOS3 and cardiomyopathy: Enhancing endothelial nitric oxide synthase (eNOS) function by restoring its coupling and subsequently reducing oxidative stress with folic acid may be a novel therapeutic approach to attenuate doxorubicin-induced cardiomyopathy (Octavia et al., 2017).